Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Restless Legs Syndrome, Clear all
Completed Not applicable Interventional Results available

Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)

NCT04874155
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
NTX100 Neuromodulation System - Active, NTX100 Neuromodulation System - Sham, NTX100 Neuromodulation System - Open-Label
Device
Lead sponsor
Noctrix Health, Inc.
Industry
Eligibility
22 Years to 79 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
San Leandro, California • Colorado Springs, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

NCT03728933
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine 1 milligram/24 hours, Rotigotine 2 milligram/24 hours, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
13 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 4 Interventional

Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

NCT03082755
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gabapentin Enacarbil, Placebo Oral Tablet
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
55 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Diagnosis and Natural History Study of Patients With Neurological Conditions

NCT00001549
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Movement Disorder, Multiple System Atrophy, Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction

NCT04698343
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Noninvasive Peripheral Nerve Stimulation (NPNS)
Device
Lead sponsor
Noctrix Health, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Downey, California • Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2Phase 3 Interventional

Safety and Efficacy of Rasagiline in Restless Legs Syndrome

NCT01192503
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
rasagiline, placebo (sugar pill)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Pinellas Park, Florida • Augusta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome

NCT00199446
View directory record Official record
Conditions
Sleep Disorder, Restless Legs Syndrome
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

NCT01931878
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
incobotulinumtoxinA, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 4 Interventional

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

NCT02117076
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
Gabapentin immediate release, Gabapentin enacarbil extended release
Drug
Lead sponsor
Theresa Zesiewicz, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Spinal Cord Stimulators on Restless Leg Syndrome

NCT07179406
View directory record Official record
Conditions
Restless Leg Syndrome (RLS), Spinal Cord Stimulation (SCS)
Interventions
H-Reflex, Somatosensory evoked potential (SSEP), Vibratory Electrophysiological Response Potential (ERP), Transcranial Magnetic Stimulation (TMS), Spinal Cord Stimulator (SCS) manipulation
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

NCT00197080
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS

NCT02397057
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
Injectafer, Placebo
Drug · Other
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • National City, California • Rancho Mirage, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

NCT00676403
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
placebo, Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 4 Interventional

An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

NCT02633683
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 600 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
11
States / cities
Redwood City, California • San Diego, California • Gulf Breeze, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

NCT00344994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
pramipexole
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Phase 4 Interventional

Butrans for Treatment of Restless Legs Syndrome

NCT02138357
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional

12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome

NCT00373542
View directory record Official record
Conditions
Restless Legs Syndrome (RLS), Restless Legs Syndrome
Interventions
ropinirole CR-RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Jasper, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

NCT00263068
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Simulated Driving Study in Restless Legs Syndrome

NCT01332318
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
XP13512, Diphenhydramine, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Disorders Management, Health and Safety in Police

NCT00207285
View directory record Official record
Conditions
Sleep Disorders, Sleep Apnea, Obstructive, Restless Legs Syndrome, Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
Interventions
Sleep Hygiene Education, Screening and Treatment of Sleep Disorders
Behavioral · Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 4 Interventional

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

NCT05003648
View directory record Official record
Conditions
Adrenoleukodystrophy, Restless Legs Syndrome
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Not applicable Interventional

The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome (RLS)

NCT04462796
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Magnesium Citrate
Dietary Supplement
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 17, 2026, 5:15 AM EDT